CryptoSlate July 31, 2026

Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug

Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug

Enlivex pledged commercially reasonable efforts to hold the shareholder vote within 60 days, while the second $400 million remains optional.

The post Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug appeared first on CryptoSlate.

You might also like

Bitcoin’s recovery faces rising derivatives expos…
Nov 01, 2026 Read
FBI confirms North Korea's role in $6 billion Bin…
Nov 01, 2026 Read
Jupiter Lend’s withdrawal liquidity rebounds from…
Oct 31, 2026 Read
Banks are owed $349B by private credit funds that…
Oct 31, 2026 Read